More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis

Figures & data

Table 1 Characteristics and laboratory parameters in patients <50 vs ≥50 years

Characteristics/parameters	Age categories		P-values
	<50 years	≥50 years
N (%)	194 (21)	746 (79)	–
Male/female (%)	113/81 (58.3)	457/289 (61.2)	0.459
IgA (%)	28/194 (14.4)	141/746 (18.9)	0.149
IgG (%)	75/194 (38.7)	341/746 (45.7)	0.078
IgD (%)	20/194 (10.3)	41/746 (5.5)	0.015
Nonsecretory (%)	6/194 (3.1)	21/746 (2.8)	0.837
Light-chain only (%)	64/194 (33.0)	195/746 (26.1)	0.057
DS stage 2/3 (%)	33/159 (17.2)	99/639 (13.4)	0.201
ISS stage 1–2/3 (%)	114/74 (60.6)	355/365 (49.3)	0.007
EMD (%)	16/162 (9.2)	47/644 (6.8)	0.316
>3 lytic lesions	82/109	334/403	0.569
Creatinine ≥2 mg/dL	41/151 (21.4)	185/553 (25.1)	0.300
β2 (mg/dL)	5.96±6.94	7.12±8.22	0.090
β2 ≥3.5 mg/dL (%)	45.8	62	<0.001
ALB (g/L)	37.3±7.5	33.5±7.5	<0.001
ALB <35 g/L (%)	37.1	57.9	<0.001
LDH (U/L)	213.06±192.17	193.29±134	0.201
Uric acid (U/L)	377.57±174.42	398.64±172.83	0.210
Creatinine (μmol/L)	149.29±201.67	141.91±145.60	0.648
CRP (mg/L)	10.69±25.83	9.96±21.80	0.718
CRP ≥10 mg/L (%)	19.0	19.4	0.891
Bone marrow plasma cell (%)	31.62±27.39	31.79±25.61	0.936
WBC	5.49±2.74	5.65±2.32	0.550
Hb	97.73±27.26	93.56±26.12	0.094
Plt	172.75±94.2	168.47±81.57	0.574

Abbreviations: DS, Durie–Salmon; ISS, International Staging System; EMD, extramedullary plasmacytoma/disease; ALB, albumin; LDH, lactate dehydrogenase; CRP, C-reactive protein; WBC, white blood cell; Hb, hemoglobin; Plt, platelet.

Table 2 Characteristics and laboratory parameters in patients <40 vs 40–50 years

Characteristics/parameters	Age categories		P-values
	<40 years	40–50 years
N (%)	49 (25)	145 (75)	–
Male/female (%)	68	55.3	0.180
Age, years	38 (23–40)	47 (41–50)	0.000
CRP (mg/L)	5.58±9.23	11.46±27.71	0.040
ESR (mm/hr)	53.70±50.57	76.24±47.78	0.050

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.

Table 3 Cytogenetics in patients <50 vs ≥50 years

Variables	Age categories, number with factor/number with valid data for factor (%)		P-values
	<50 years	≥50 years
Any clonal CA	7/33 (21)	32/120 (27)	0.524
Del 13a	3/33 (9)	9/120 (8)	0.767
Del 13b	13/37 (35)	58/141 (41)	0.507
1q21 amplificationb	49/87 (33)	139/313 (44)	0.064
Del P53b	17/91 (19)	61/351 (17)	0.771

Notes:

a Cytogenetics;

b FISH.

Abbreviations: CA, cytogenetic abnormality by G-banding; FISH, fluorescence in situ hybridization; Del, deletion.

Table 4 Immunophenotype in patients <50 vs ≥50 years

Variables	Age categories, number with factor/number with valid data for factor (%)		P-values
	<50 years	≥50 years
CD38	62/62 (100)	261/262 (100)	1.0
CD138	62/62 (100)	264/267 (99)	1.0
CD56	32/56 (57)	163/246 (66)	0.198
CXCR4	18/41 (44)	60/184 (33)	0.169
CD20	8/51 (16)	53/217 (25)	0.181
CD117	22/52 (42)	89/219 (41)	0.826
CD9	30/46 (65)	120/194 (62)	0.672
CD28	8/31 (26)	27/141 (19)	0.404
CD200	36/80 (45)	112/184 (61)	0.017

Abbreviation: CXCR, chemokine receptor.

Figure 1 OS in younger and older patients.

Abbreviation: OS, overall survival.

Figure 2 PFS in younger and older patients.

Abbreviation: PFS, progression-free survival.

Figure 3 PFS in younger and older patients receiving bortezomib and MP/VAD.

Abbreviations: PFS, progression-free survival; MP, melphalan-prednisolone; VAD, vincristine-adriamycin-dexamethasone.

Figure 4 OS in younger and older patients receiving bortezomib and MP/VAD.

Abbreviations: OS, overall survival; MP, melphalan-prednisolone; VAD, vincristine-adriamycin-dexamethasone.

Figure 5 PFS in younger and older patients receiving MP/VAD treatment.

Abbreviations: PFS, progression-free survival; MP, melphalan-prednisolone; VAD, vincristine-adriamycin-dexamethasone.

Figure 6 OS in younger and older patients receiving MP/VAD treatment.

Abbreviations: OS, overall survival; MP, melphalan-prednisolone; VAD, vincristine-adriamycin-dexamethasone.